Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

RWJ-67657 advances to human studies: PK and cytokine inhibition determined in healthy subjects

Nov. 7, 2000

New MEK inhibitor from DuPont and its use in inflammation and cancer

Nov. 6, 2000

Pyridine- and pyrimidine-based compounds from AstraZeneca for cytokine-mediated disorders

Nov. 3, 2000

Pfizer reports preparation and use of new MMP-inhibitory hydroxamic acids

Nov. 3, 2000

Scios begins phase I trial with oral p38 kinase inhibitor; preclinical results reported

Nov. 3, 2000

New amide inhibitors of cytokine and interleukin production from AstraZeneca

Nov. 2, 2000

Clinical improvement seen in patients with undifferentiated spondyloarthropathy treated with subreum

Nov. 2, 2000

Danish phase I trial of anti-CD4 MAb reported at ACR 2000 meeting

Oct. 31, 2000

Boehringer Ingelheim presents new group of inhibitors of inflammatory cytokines

Oct. 31, 2000

Inflammatory cytokine-reducing compounds designed at Celgene

Oct. 30, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors
BioWorld Science
Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...